Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: A randomized, double-blind, placebo-, and active-controlled thorough QT study

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 6, 2012, Pages 696-706

  Malik, M ^a   Van Gelderen, E M ^b   Lee, J H ^c   Kowalski, D L ^c   Yen, M ^d   Goldwater, R ^d   Mujais, S K ^c   Schaddelee, M P ^b   De Koning, P ^c   Kaibara, A ^e   Moy, S S ^c   Keirns, J J ^c  

^a St Paul's Cardiac Electrophysiology   (United Kingdom)

^b Astellas Pharma Global Development   (Netherlands)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d PAREXEL INTERNATIONAL   (United States)

^e ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MIRABEGRON; MOXIFLOXACIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART REPOLARIZATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN EXPERIMENT; ISCHIALGIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE DRUG DOSE; TOOTH PAIN;

ACETANILIDES; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; QUINOLINES; SEX CHARACTERISTICS; THIAZOLES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 84869491480     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.181     Document Type: Article

References (43)

1. Takasu, T. et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2- hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J. Pharmacol. Exp. Ther. 321, 642-647 (2007). (Pubitemid 46624504)
2. Abrams, P., Artibani, W., Cardozo, L., Dmochowski, R., van Kerrebroeck, P. & Sand, P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol. Urodyn. 28, 287 (2009).
3. Wein, A.J. & Rovner, E.S. Definition and epidemiology of overactive bladder. Urology 60, 7-12; discussion 12 (2002). (Pubitemid 36009213)
4. Athanasopoulos, A. & Giannitsas, K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv. Urol. 2011, 820816 (2011).
5. Khullar, V., Cambronero, J., Stroeberg, P., Angulo, J., Boerrigter, P. & Wooning, M. The efficacy and tolerability of mirabegron, a potent and selective β3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder-results from a European-Australian phase III trial. Abstract 328. Eur. Urol. Suppl. 10, 278-279 (2011).
6. Nitti, V., Herschorn, S., Lee, M. & Martin, N. Efficacy and tolerability of oncedaily mirabegron, a potent and selective β3-adrenoceptor agonist, in patients with overactive bladder-results from a North American Phase III trial. Abstract 92. Eur. Urol. Suppl. 10, 278 (2011).
7. Food and Drug Administration. International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed. Regist. 70, 61134-61135 (2005).
8. Fenichel, R.R. et al. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. 15, 475-495 (2004). (Pubitemid 38510109)
9. Garnett, C.E. et al. Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am. Heart J. 163, 912-930 (2012).
10. Fridericia, L.S. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920. Ann. Noninvasive Electrocardiol. 8, 343-351 (2003). (Pubitemid 38569971)
11. Malik, M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J. Cardiovasc. Electrophysiol. 12, 411-420 (2001). (Pubitemid 32324653)
12. Malik, M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin. Electrophysiol. 25, 209-216 (2002). (Pubitemid 34214594)
13. Malik, M., F?bom, P., Batchvarov, V., Hnatkova, K. & Camm, A.J. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87, 220-228 (2002). (Pubitemid 34177674)
14. Malik, M., Hnatkova, K., Novotny, T. & Schmidt, G. Subject-specific profiles of QT/RR hysteresis. Am. J. Physiol. Heart Circ. Physiol. 295, H2356-H2363 (2008).
15. Hnatkova, K., Toman, O., Sisakova, M., Novotny, T. & Malik, M. Dynamic properties of selected repolarization descriptors. J. Electrocardiol. 43, 588-594 (2010).
16. Coyne, K.S., Sexton, C.C., Vats, V., Thompson, C., Kopp, Z.S. & Milsom, I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77, 1081-1087 (2011).
17. Malik, M., Zhang, J., Johannesen, L., Hnatkova, K. & Garnett, C. Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability. Heart Rhythm 8, 1777-1785 (2011).
18. Malik, M., Garnett, C.E. & Zhang, J. Thorough QT studies: questions and quandaries. Drug Saf. 33, 1-14 (2010).
19. Bloomfield, D.M. et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin. Pharmacol. Ther. 84, 475-480 (2008).
20. Malik, M., Hnatkova, K. & Batchvarov, V. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation. Pacing Clin. Electrophysiol. 27, 791-800 (2004). (Pubitemid 38758763)
21. Malik, M., Hnatkova, K., Schmidt, A. & Smetana, P. Accurately measured and properly heart-rate corrected QTc intervals show little daytime variability. Heart Rhythm 5, 1424-1431 (2008).
22. Roden, D.M. A practical approach to torsade de pointes. Clin. Cardiol. 20, 285-290 (1997). (Pubitemid 27120167)
23. Chapple, C., Herschorn, S., Abrams, P., Sun, F., Brodsky, M. & Guan, Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur. Urol. 56, 534-541 (2009).
24. Sawamoto, T.et al. Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin. Pharmacol. Ther. 89, S21 (2011).
25. van Gelderen, E., Li, Q. & Meijer, J. An exploratory comparison of the single dose pharmacokinetics of the beta 3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin. Pharmacol. Ther. 85 (suppl. 1), S88 (2009).
26. Eltink C. et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int. J. Clin. Pharmacol. Ther. (2012); e-pub ahead of print 4 September 2012.
27. Lin, J. & Yamazaki, M. Role of P-glycoprotein in pharmacokinetics- clinical implications. Clin. Pharmacokinet. 42, 59-98 (2003).
28. Andersson, K.E., Campeau, L. & Olshansky, B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br. J. Clin. Pharmacol. 72, 186-196 (2011).
29. Connolly, M.J., Astridge, P.S., White, E.G., Morley, C.A. & Cowan, J.C. Torsades de pointes ventricular tachycardia and terodiline. Lancet 338, 344-345 (1991).
30. McLeod, A.A., Thorogood, S. & Barnett, S. Torsades de pointes complicating treatment with terodiline. BMJ 302, 1469 (1991).
31. Serra, D.B. et al. QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J. Clin. Pharmacol. 45, 1038-1047 (2005). (Pubitemid 41192363)
32. Malhotra, B., Wood, N., Sachse, R. & Gandelman, K. Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int. J. Clin. Pharmacol. Ther. 48, 309-318 (2010).
33. Allergan. Sanctura prescribing information 02/2011 . Last update: February 2011.
34. Astellas. Vesicare prescribing information. Last update: April 2011 .
35. Malhotra, B.K., Glue, P., Sweeney, K., Anziano, R., Mancuso, J. & Wicker, P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin. Pharmacol. Ther. 81, 377-385 (2007). (Pubitemid 46364489)
36. Hnatkova, K., Smetana, P., Toman, O., Bauer, A., Schmidt, G. & Malik, M. Systematic comparisons of electrocardiographic morphology increase the precision of QT interval measurement. Pacing Clin. Electrophysiol. 32, 119-130 (2009).
37. Acar, B., Yi, G., Hnatkova, K. & Malik, M. Spatial, temporal and wavefront direction characteristics of 12-lead T-wave morphology. Med. Biol. Eng. Comput. 37, 574-584 (1999). (Pubitemid 29488393)
38. Batchvarov, V., Hnatkova, K. & Malik, M. Assessment of noise in digital electrocardiograms. Pacing Clin. Electrophysiol. 25, 499-503 (2002). (Pubitemid 34438255)
39. Malik, M. et al. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin. Pharmacol. Ther. 84, 595-603 (2008).
40. Batchvarov, V.N. et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am. J. Physiol. Heart Circ. Physiol. 282, H2356-H2363 (2002). (Pubitemid 34663047)
41. Liu, G.F., Lu, K., Mogg, R., Mallick, M. & Mehrotra, D.V. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat. Med. 28, 2509-2530 (2009).
42. Kenward, M.G. & Roger, J.H. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53, 983-997 (1997). (Pubitemid 27391027)
43. Garnett, C.E. et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J. Clin. Pharmacol. 48, 13-18 (2008). (Pubitemid 350292272)